Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

NEUROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of neurology, holding an esteemed Q1 category ranking in clinical neurology as of 2023. Established in 1951, this journal has been a critical resource for the dissemination of cutting-edge research and clinical advancements, with an impressive Scopus rank of 24 out of 400, placing it in the 94th percentile among its peers. NEUROLOGY serves as a vital platform for neurologists, researchers, and medical professionals seeking to stay abreast of the latest findings and innovations in the treatment and understanding of neurological disorders. With its rigorous peer-review process and commitment to excellence, NEUROLOGY remains essential reading for all individuals dedicated to advancing the science and practice of neurology, contributing significantly to the ongoing dialogue in this vital area of medicine.

The Lancet Neurology is a premier academic journal published by Elsevier Science Inc, specializing in the field of neurology. With a robust impact factor that signifies its authoritative presence, it consistently ranks in the Q1 category for clinical neurology according to the 2023 standards, positioning itself as the leading journal in its domain, ranking #1 out of 400 in Scopus' neurology rankings and placing in the 99th percentile. Since its establishment in 2002, it has provided a vital platform for disseminating innovative research and clinical advances related to neurological disorders. The journal’s precise focus includes cutting-edge studies on neurodegenerative diseases, stroke, epilepsy, and neuroimaging, which are essential for advancing clinical practice and improving patient outcomes. While it does not offer open access, readers can find high-impact research published monthly, making it indispensable for practitioners, researchers, and students eager to stay at the forefront of neurological science.

Canadian Journal of Neurological Sciences, published by Cambridge University Press, stands as a reputable source of knowledge in the field of neurology, dedicated to advancing research and clinical practice. With an ISSN of 0317-1671 and an E-ISSN of 2057-0155, this journal has been a cornerstone for the exchange of ideas since its inception in 1974 and will continue to cater to the academic community until 2024. Recognized in the top quartile (Q2) in various categories including Medicine (miscellaneous) and Neurology (clinical), its articles engage a broad audience, ranging from established researchers to students seeking to deepen their understanding of neurological sciences. Although the journal is not an open-access publication, it provides vital insights and research findings that contribute significantly to its fields. With a Scopus rank of #183 in clinical neurology and a percentile ranking that reflects its commendable standing, the Canadian Journal of Neurological Sciences is indispensable for those committed to the exploration and treatment of neurological disorders.

NEUROLOGIC CLINICS, published by W B SAUNDERS CO-ELSEVIER INC, stands as a leading journal in the field of clinical neurology, boasting an impressive impact factor that reflects its significant contributions to neurological research and clinical practice. With an ISSN of 0733-8619 and E-ISSN of 1557-9875, this journal provides a critical platform for the dissemination of innovative research, case studies, and reviews focusing on various aspects of neurology, from diagnosis to treatment interventions. As part of its commitment to advancing the understanding of neurological disorders, NEUROLOGIC CLINICS is categorized in the Q2 quartile for Neurology (clinical) in 2023, indicating its robust standing within the academic community. It is recognized for its rigorous peer-review process and is indexed in Scopus, ranking #147 out of 400 in its field with a notable 63rd percentile. The journal, which dates back to 1983 and continues to publish vital findings up to 2024, is an invaluable resource for researchers, healthcare professionals, and students dedicated to enhancing their knowledge and clinical skills in neurology. Subscribe now to stay abreast of current advancements and expand your expertise in this dynamic field.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

NEUROLOGIA, an esteemed journal published by ELSEVIER ESPANA SLU, stands at the forefront of the field of neurology, with a dedicated focus on innovative research and clinical practice since its inception in 1973. As an Open Access journal since 2017, it champions the dissemination of knowledge, allowing researchers, professionals, and students alike to access cutting-edge findings in neurology without barriers. With an impressive Scopus rank of #115 in the clinical neurology category, placing it in the 71st percentile, NEUROLOGIA is categorized as Q3 in both general medicine and clinical neurology, reflecting its impact and relevance in a rapidly evolving field. Based in Barcelona, Spain, the journal's commitment to advancing understanding of neurological conditions is underscored by its rigorous peer-review process and engagement with a global audience. As it continues to publish vital research that shapes clinical practices and informs policy, NEUROLOGIA remains an integral resource for those striving to improve outcomes in neurology.

Current Neuropharmacology is a premier journal dedicated to advancing the field of neuropharmacology, published by Bentham Science Publishers Ltd in the United Arab Emirates. As a leader in its domain, this journal has achieved a remarkable position in 2023, with Q1 rankings across several categories including Medicine (miscellaneous), Neurology, and Pharmacology. With a robust focus on the latest research related to pharmacological treatments and their neurological implications, Current Neuropharmacology features cutting-edge studies that inform clinical practices and psychiatric care. Although not open access, the journal offers both print and electronic formats to cater to a diverse audience of researchers, healthcare professionals, and students keen on accessing vital information in neuropharmacology. Its high impact within the academia is underscored by impressive Scopus rankings, confirming its importance as a vital resource for the ongoing exploration of mental health and neurotherapeutic innovations. With an engaging scope that encompasses emerging discoveries and clinical advancements, Current Neuropharmacology continues to be an essential platform for scholarly communication in the evolving landscape of neuroscience and pharmacology.

Current Journal of Neurology, published by Tehran University of Medical Sciences, is an esteemed Open Access journal dedicated to advancing the field of neurology. Since its inception in 2011, the journal has provided a platform for innovative research and critical discourse in neurology and clinical neurology, with a focus on the latest advancements and methodologies. Although the journal currently holds a Q4 quartile ranking in both neurology and clinical neurology, its goal is to foster the global dissemination of knowledge and ideas relevant to the complexities of neurological disorders. Researchers, professionals, and students exploring this dynamic field will find valuable insights, as the journal aims to bridge the gap between emerging research and clinical application. Based in Tehran, Iran, the Current Journal of Neurology welcomes contributions that enhance understanding and treatment of neurological conditions, thereby promoting evidence-based practices across the globe.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.